Copenhagen-based SNIPR Biome, a biotech company focused on developing precision medicines through CRISPR technology for microbial gene therapy, has successfully secured €35M in a Series B funding round.
The investment comes from new investors, including the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D), as well as existing investors such as Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.
The announcement comes around eight months after raising €20M in venture debt from the European Investment Bank (EIB) to help combat antimicrobial resistance.
Fund utilisation
This funding will support the development of a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF).
The funding will support the development of a CRISPR-based microbial intervention aimed at eliminating antibiotic resistance genes present in humans across different bacterial species and environments.
Additionally, it will facilitate the clinical advancement of the company’s CRISPR-based product, SNIPR001, for patients with hematologic cancer, including the ongoing Phase 1b trial.
SNIPR Biome: Pioneering the development of CRISPR-medicine
Led by Christian Grøndahl, SNIPR Biome is a clinical-stage biotech company pioneering the development of CRISPR-medicine.
The Danish company is pioneering a novel use of CRISPR-Cas technology to better treat and prevent human diseases through precision killing of bacteria or gene modification.
SNIPR Biome was the first company to orally dose humans with a CRISPR therapeutic and the first company to have been granted US and European patents for the use of CRISPR for targeting microbiomes.
SNIPR001 is currently being evaluated in a Phase 1b (NCT06938867) study at eight cancer centres in the US and is co-funded by CARB-X.
SNIPR technology is used in collaborations with CARB-X, Gates Foundation, Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Centre.
“This financing marks a pivotal milestone for SNIPR BIOME as we advance the clinical development of SNIPR001 for the prevention of bloodstream infections and continue to expand our infectious disease pipeline targeting pathogens of critical importance,” says Christian Grøndahl, Chief Executive Officer and Co-Founder of SNIPR BIOME, and he continued. “This support shows the importance of addressing antimicrobial resistance and infectious disease and the unique position of SNIPR BIOME in the development landscape.”
